189956-01-2

Upstream product

• 209518-78-5 (E)-1-(methylsulfonyl)-4(4,4,4-trifluoro-2-methylbut-1-en-1-yl)benzene 
• 209518-74-1 ethyl (E)-2-methyl-3-(4-(methylsulfonyl)phenyl)acrylate 
• 209518-73-0 (2E) Ethyl 2-methyl-3-(4-methylthiophenyl)propenate 
• 209518-77-4 1-((E)-3-Iodo-2-methyl-propenyl)-4-methanesulfonyl-benzene 
• 3446-89-7 4-(Methylthio)benzaldehyde 
• 209518-82-1 (1R,2R)-4,4,4-Trifluoro-1-(4-methanesulfonyl-phenyl)-2-methyl-butane-1,2-diol 

Downstream Products

• 189955-09-7 (5R)-3-(3,4-difluorophenoxy)-5-methyl-4-(4-methylsulfonyl) phenyl-5-(2,2,2-trifluoroethyl)-5H-furan-2-one 
• 189955-05-3 (5R)-3-(4-fluorophenoxy)-5-methyl-4-(4-methylsulfonyl)phenyl-5-(2,2,2-trifluoroethyl)-5H-furan-2-one 

Relevant academic research and scientific papers

(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors

The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.

An efficient asymmetric synthesis of a potent COX-2 inhibitor L-784,512

An efficient enantioselective synthesis of L-784,512 featuring a Horner- Emmons reaction, a new one-pot trifluoromethylation, and the Sharpless asymmetric dihydroxylation is described.

3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.